US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
HUP9901478A3
(en)
|
1996-05-10 |
1999-11-29 |
Icos Corp Bothell |
Carboline derivatives, their use, production thereof and medicaments containing the same
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
DE69833254T2
(de)
*
|
1997-06-23 |
2006-11-02 |
Cellegy Pharmaceuticals, Inc., Brisbane |
Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
JP2002539247A
(ja)
*
|
1999-03-24 |
2002-11-19 |
ハーバー ブランチ オーシャノグラフィック インスティテューション インク. |
マンズアミンの抗炎症作用の使用
|
US6943166B1
(en)
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
NO20002097L
(no)
*
|
1999-04-30 |
2001-10-26 |
Lilly Icos Llc |
Fremstillingsgjenstander
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
EA004872B1
(ru)
|
1999-08-03 |
2004-08-26 |
ЛИЛЛИ АЙКОС эЛ-эЛ-Си |
β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
|
CN1378547A
(zh)
|
1999-10-11 |
2002-11-06 |
辉瑞大药厂 |
用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物
|
TW200400821A
(en)
*
|
1999-11-02 |
2004-01-16 |
Pfizer |
Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
CN1436080A
(zh)
|
2000-04-19 |
2003-08-13 |
利利艾科斯有限公司 |
环gmp-特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
WO2001094345A2
(en)
*
|
2000-06-07 |
2001-12-13 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
DE60121587T2
(de)
*
|
2000-06-23 |
2007-09-13 |
Lilly Icos Llc, Wilmington |
Zyklische gmp-spezifische phosphodiesteraseinhibitoren
|
AU2001261707A1
(en)
*
|
2000-06-23 |
2002-01-08 |
Lilly Icos Llc |
Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
|
JP2004501919A
(ja)
*
|
2000-06-26 |
2004-01-22 |
リリー アイコス リミテッド ライアビリティ カンパニー |
化学化合物
|
US7176228B2
(en)
*
|
2000-07-24 |
2007-02-13 |
Bayer Cropscience Ag |
Pyrazole biphenylcarboxamides
|
EP1305313A1
(de)
*
|
2000-08-02 |
2003-05-02 |
Lilly Icos LLC |
Kondensierte heterocyclische derivate als phosphodiesterase-inhibitoren
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
EP1325007B1
(de)
*
|
2000-10-02 |
2005-06-15 |
Lilly Icos LLC |
Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
|
ES2248399T3
(es)
|
2000-10-02 |
2006-03-16 |
Lilly Icos Llc |
Derivados de piridoindol condensado.
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
EP1211313A3
(de)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation der PDE11A-AKtivität
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
ES2271080T3
(es)
*
|
2000-11-06 |
2007-04-16 |
Lilly Icos Llc |
Derivados de indol como inhibidores de pde5.
|
EP1383765B1
(de)
*
|
2001-04-25 |
2006-12-13 |
Lilly Icos LLC |
Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
|
CA2445620C
(en)
*
|
2001-06-05 |
2008-07-08 |
Lilly Icos Llc |
Tetracyclic compounds as pde5-inhibitors
|
JP2004536816A
(ja)
|
2001-06-05 |
2004-12-09 |
リリー アイコス リミテッド ライアビリティ カンパニー |
Pde5阻害剤としてのカルボリン誘導体
|
DE60226970D1
(de)
*
|
2001-06-05 |
2008-07-17 |
Lilly Icos Llc |
Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
|
ATE335742T1
(de)
*
|
2001-06-21 |
2006-09-15 |
Lilly Icos Llc |
Carbolinderivate als pdev inhibitoren
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
WO2003042216A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
DK1448562T3
(da)
|
2001-11-14 |
2007-09-24 |
Ortho Mcneil Pharmaceutical Co |
Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
CN1655820A
(zh)
*
|
2002-05-23 |
2005-08-17 |
辉瑞大药厂 |
Pde5抑制剂与ace抑制剂的药物组合
|
SI1509525T1
(sl)
|
2002-05-31 |
2006-12-31 |
Schering Corp |
Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
BR0313070B1
(pt)
*
|
2002-07-31 |
2014-09-09 |
Icos Corp |
Métodos para preparação de um diastereômero desejado de uma tetraidro-beta-carbolina e para preparação de um composto
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
CA2509605C
(en)
|
2002-12-13 |
2010-10-05 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
EA200501548A1
(ru)
|
2003-04-01 |
2006-02-24 |
Апплайд Резеч Системз Арс Холдинг Н.В. |
Ингибиторы фосфодиэстераз при бесплодии
|
OA13050A
(en)
|
2003-04-29 |
2006-11-10 |
Pfizer Ltd |
5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
|
NZ544040A
(en)
|
2003-05-22 |
2009-03-31 |
Nycomed Gmbh |
Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
|
EP1644021B1
(de)
|
2003-06-13 |
2012-08-22 |
Ironwood Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
|
US7872133B2
(en)
|
2003-06-23 |
2011-01-18 |
Ono Pharmaceutical Co., Ltd. |
Tricyclic heterocycle compound
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
EP1699436A2
(de)
*
|
2003-12-12 |
2006-09-13 |
Myogen, Inc. |
Enoximon-formulierungen und ihre verwendung bei der behandlung von herzhypertrophy und herzinsuffizienz
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
US20060025463A1
(en)
*
|
2004-03-22 |
2006-02-02 |
Michael Bristow |
Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
|
CA2560538A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
DE602005011784D1
(de)
|
2004-04-07 |
2009-01-29 |
Pfizer |
Pyrazoloä4,3-düpyrimidine
|
WO2005116030A1
(en)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
A process for the preparation of tadalafil
|
WO2006007213A1
(en)
*
|
2004-06-23 |
2006-01-19 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
US8299083B2
(en)
|
2004-08-17 |
2012-10-30 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
EP2216329A1
(de)
|
2004-10-28 |
2010-08-11 |
Dr. Reddy's Laboratories Ltd. |
Verfahren zur Herstellung von Tadalafil
|
US20060111571A1
(en)
*
|
2004-11-02 |
2006-05-25 |
Shlomit Wizel |
Tadalafil crystal forms and processes for preparing them
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
ES2459742T3
(es)
|
2004-12-22 |
2014-05-12 |
Ono Pharmaceutical Co., Ltd. |
Compuesto tricíclico y uso del mismo
|
WO2006091974A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil having a large particle size and a process for preparation thereof
|
CA2596667A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Process of synthesizing tadalafil
|
KR20070099034A
(ko)
*
|
2005-02-25 |
2007-10-08 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타달라필의 정제 방법
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
ES2278552T1
(es)
*
|
2005-04-12 |
2007-08-16 |
Teva Pharmaceutical Industries Ltd |
Preparacion de intermediarios de tadalafil.
|
DK2366393T3
(da)
|
2005-04-19 |
2013-10-21 |
Takeda Gmbh |
Roflumilast til behandlingen af pulmonal hypertension
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
US8227475B2
(en)
|
2005-05-12 |
2012-07-24 |
Pfizer Inc. |
Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
EP2324886A1
(de)
|
2005-07-29 |
2011-05-25 |
Concert Pharmaceuticals Inc. |
Neue deuterierte Analoga des Tadalafils
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
PL1912650T3
(pl)
|
2005-08-03 |
2018-01-31 |
Sprout Pharmaceuticals Inc |
Zastosowanie flibanseryny w leczeniu otyłości
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
EP2258359A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
|
EP1937217A2
(de)
*
|
2005-09-13 |
2008-07-02 |
Elan Pharma International Limited |
Nanoteilchenförmige tadalafil-formulierungen
|
TR201815853T4
(tr)
|
2005-10-12 |
2018-11-21 |
Besins Healthcare Sarl |
Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
|
EP1940389A2
(de)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation von neurogenese durch pde-hemmung
|
CA2626134C
(en)
|
2005-10-29 |
2013-12-24 |
Boehringer Ingelheim International Gmbh |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007100387A2
(en)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing tadalafil
|
CN101355876B
(zh)
|
2005-11-09 |
2012-09-05 |
康宾纳特克斯公司 |
一种适用于眼部给药的组合物
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
EP1991212A1
(de)
*
|
2006-03-08 |
2008-11-19 |
Braincells, Inc. |
Neurogenesemodulation durch nootropika
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007110734A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of tadalafil
|
WO2007124045A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Ampla Pharmaceuticals, Inc. |
Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
EP2021000A2
(de)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenese mittels angiotensin-modulation
|
MX2008014320A
(es)
*
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
JP2009541443A
(ja)
|
2006-06-30 |
2009-11-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
尿失禁及び関連疾患の治療のためのフリバンセリン
|
BRPI0621852A2
(pt)
*
|
2006-07-07 |
2011-12-20 |
Teva Pharma |
compostos sólidos consistindo de tadalafil e pelo menos um veìculo
|
CA2657346A1
(en)
|
2006-07-21 |
2008-01-24 |
Novartis Ag |
Formulations for benzimidazolyl pyridyl ethers
|
JP5793828B2
(ja)
|
2006-08-14 |
2015-10-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
フリバンセリンの製剤及びその製造方法
|
EP2056797A2
(de)
|
2006-08-25 |
2009-05-13 |
Boehringer Ingelheim International GmbH |
System mit kontrollierter freisetzung und verfahren zu seiner herstellung
|
AR062501A1
(es)
*
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
EP2068872A1
(de)
*
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Kombinationen mit einem 4-acylaminopyridin-derivat
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2066355A2
(de)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
|
AU2007333115B2
(en)
|
2006-12-12 |
2013-01-10 |
Gilead Sciences, Inc. |
Composition for treating a pulmonary hypertension
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
NZ579169A
(en)
*
|
2007-02-12 |
2012-05-25 |
Dmi Biosciences Inc |
Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor
|
KR20130122023A
(ko)
|
2007-02-12 |
2013-11-06 |
디엠아이 바이오사이언시스 인코포레이티드 |
트라마돌의 부작용을 감소시키는 방법
|
WO2008103470A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
MX2009011588A
(es)
*
|
2007-04-25 |
2009-11-05 |
Teva Pharma |
Formas de dosificacion solidas que comprenden tadalafil.
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
DE102007028869A1
(de)
*
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
KR20100027170A
(ko)
|
2007-06-29 |
2010-03-10 |
랜박시 래보러터리스 리미티드 |
테트라사이클릭 화합물의 중간체의 제조 방법
|
EP2033962A1
(de)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Tetrazyclische Indolopyridinderivate als EG5-Hemmer
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
EP2107059A1
(de)
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Umwandlung von Tryptophan in ß-Carbolinderivate
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
US8580801B2
(en)
*
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
EP2181997A1
(de)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
Verfahren zur Herstellung von Tadalafil
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
JP2012513464A
(ja)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
ホスホジエステラーゼ阻害剤及びその使用
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US8586587B2
(en)
|
2009-02-26 |
2013-11-19 |
Thar Pharmaceuticals, Inc. |
Crystalline molecular complex of tadalafil and methylparaben
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
JP2013523809A
(ja)
|
2010-04-05 |
2013-06-17 |
エスケー ケミカルズ カンパニー リミテッド |
Pde5抑制剤を含む皮膚しわ改善用組成物
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
SI2637664T1
(sl)
|
2010-10-15 |
2017-07-31 |
Gilead Sciences, Inc. |
Sestavki in postopki zdravljenja pljučne hipertenzije
|
US8829023B2
(en)
|
2011-02-10 |
2014-09-09 |
Interquim, S.A. |
Process for obtaining compounds derived from tetrahydro-β-carboline
|
WO2012107092A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
WO2012107090A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Granulated composition comprising tadalafil and a disintegrant
|
WO2012107541A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
EP2535049A1
(de)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil zur Behandlung von Demenz
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
WO2013067309A1
(en)
|
2011-11-04 |
2013-05-10 |
Xion Pharmaceutical Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
EP2804603A1
(de)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
WO2014092661A1
(en)
|
2012-01-18 |
2014-06-19 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
WO2013109225A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical tablet formulations comprising ceftibuten
|
WO2013109223A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
WO2013129889A2
(ko)
|
2012-02-28 |
2013-09-06 |
주식회사 서울제약 |
실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
|
EP2903619B1
(de)
|
2012-10-05 |
2019-06-05 |
Robert I. Henkin |
Phosphodiesterasehemmer zur behandlung von geschmacks- und geruchsstörungen
|
US9750743B2
(en)
|
2012-12-04 |
2017-09-05 |
Aribio Inc. |
Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
WO2014100733A1
(en)
|
2012-12-21 |
2014-06-26 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating calcific aortic valve stenosis
|
AU2014220801A1
(en)
|
2013-02-21 |
2015-09-10 |
Adverio Pharma Gmbh |
Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
EP3022205B1
(de)
|
2013-07-17 |
2020-02-05 |
The Trustees of Columbia University in the City of New York |
Neuartige phosphodiesterasehemmer und verwendungen davon
|
US20160317542A1
(en)
|
2013-12-09 |
2016-11-03 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
US10598672B2
(en)
|
2014-02-18 |
2020-03-24 |
Cyrano Therapeutics, Inc. |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
JP6687550B2
(ja)
|
2014-06-23 |
2020-04-22 |
セルジーン コーポレイション |
肝疾患又は肝機能異常を治療するためのアプレミラスト
|
EP2962685B1
(de)
|
2014-06-30 |
2020-01-08 |
Montero Gida Sanayi Ve Ticaret A.S. |
Im mund zerfallende formulierungen von tadalafil
|
EP2962684A1
(de)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Im mund zerfallende formulierungen von tadalafil
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
SI3466951T1
(sl)
|
2014-07-23 |
2022-05-31 |
Krka, D.D., Novo Mesto |
Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
ES2774048T3
(es)
*
|
2015-06-26 |
2020-07-16 |
Chongqing Dikang Erle Pharma Co Ltd |
Nuevo inhibidor de la fosfodiesterasa de tipo 5 y su aplicación
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
EP3554507A1
(de)
|
2016-12-14 |
2019-10-23 |
Respira Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von pulmonaler hypertonie und anderen lungenerkrankungen
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
BR112021024894A2
(pt)
|
2019-07-15 |
2022-01-25 |
Biolab Sanus Farmaceutica Ltda |
Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|